Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study

Ferdinand W. N. M. Wit; Daniel H. Blanckenberg; Kees Brinkman; Jan M. Prins; Marchina E. van der Ende; Margriet M. E. Schneider; Jan-Willem Mulder; Frank de Wolf; Joep M. A. Lange

Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study

Ferdinand W. N. M. Wit
, Daniel H. Blanckenberg
, Kees Brinkman
, Jan M. Prins
, Marchina E. van der Ende
, Margriet M. E. Schneider
, Jan-Willem Mulder
, Frank de Wolf
, Joep M. A. Lange

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

We studied the dynamics of CD4 cell counts after the interruption of virologically successful highly active antiretroviral therapy (HAART) in 139 patients. Changes in CD4 cell counts during HAART interruption followed a biphasic pattern: an initial rapid decline during the first month followed by a slow decrease. During 48 weeks of follow-up mean CD4 cell counts remained just above the mean pre-HAART level. This limits the feasibility of structured treatment interruptions for patients with low nadir CD4 cell counts

Original language	English
Pages (from-to)	345-348
Journal	AIDS (London, England)
Volume	19
Issue number	3
Publication status	Published - 2005

Cite this

@article{ccce2ec304ac473fac1cc27e400e2ed5,

title = "Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study",

abstract = "We studied the dynamics of CD4 cell counts after the interruption of virologically successful highly active antiretroviral therapy (HAART) in 139 patients. Changes in CD4 cell counts during HAART interruption followed a biphasic pattern: an initial rapid decline during the first month followed by a slow decrease. During 48 weeks of follow-up mean CD4 cell counts remained just above the mean pre-HAART level. This limits the feasibility of structured treatment interruptions for patients with low nadir CD4 cell counts",

author = "Wit, \{Ferdinand W. N. M.\} and Blanckenberg, \{Daniel H.\} and Kees Brinkman and Prins, \{Jan M.\} and \{van der Ende\}, \{Marchina E.\} and Schneider, \{Margriet M. E.\} and Jan-Willem Mulder and \{de Wolf\}, Frank and Lange, \{Joep M. A.\}",

year = "2005",

language = "English",

volume = "19",

pages = "345--348",

journal = "AIDS (London, England)",

issn = "0269-9370",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study

AU - Wit, Ferdinand W. N. M.

AU - Blanckenberg, Daniel H.

AU - Brinkman, Kees

AU - Prins, Jan M.

AU - van der Ende, Marchina E.

AU - Schneider, Margriet M. E.

AU - Mulder, Jan-Willem

AU - de Wolf, Frank

AU - Lange, Joep M. A.

PY - 2005

Y1 - 2005

N2 - We studied the dynamics of CD4 cell counts after the interruption of virologically successful highly active antiretroviral therapy (HAART) in 139 patients. Changes in CD4 cell counts during HAART interruption followed a biphasic pattern: an initial rapid decline during the first month followed by a slow decrease. During 48 weeks of follow-up mean CD4 cell counts remained just above the mean pre-HAART level. This limits the feasibility of structured treatment interruptions for patients with low nadir CD4 cell counts

AB - We studied the dynamics of CD4 cell counts after the interruption of virologically successful highly active antiretroviral therapy (HAART) in 139 patients. Changes in CD4 cell counts during HAART interruption followed a biphasic pattern: an initial rapid decline during the first month followed by a slow decrease. During 48 weeks of follow-up mean CD4 cell counts remained just above the mean pre-HAART level. This limits the feasibility of structured treatment interruptions for patients with low nadir CD4 cell counts

M3 - Article

C2 - 15718848

SN - 0269-9370

VL - 19

SP - 345

EP - 348

JO - AIDS (London, England)

JF - AIDS (London, England)

IS - 3

ER -

Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study

Abstract

Fingerprint

Cite this